EPHA2, EPHA4, and EPHA6 Expression in Uveal Melanomas: Searching for the Culprits of Neoplasia.
biomarkers
cancer
ephrins
prognosis
uveal melanomas
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
19 Apr 2022
19 Apr 2022
Historique:
received:
22
02
2022
revised:
07
04
2022
accepted:
14
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Uveal melanomas (UMs) comprise the most common primary intraocular malignancies in adults, with the eye representing the second most common site for melanoma, following the skin. Prognosis remains poor, with approximately half of the cases presenting with metastatic disease at the time of diagnosis. Erythropoietin-producing human hepatocellular receptors (EPHs) comprise the largest known family of tyrosine receptors, in which, along with their ligands, ephrins, play an important role in a plethora of processes in human physiology, and are implicated in key steps of carcinogenesis. In the present study, EPHA2, EPHA4, and EPHA6 immunohistochemical expressions were investigated in UM tissues and further correlated to a multitude of clinicopathological parameters, including disease stage and patients’ overall survival (OS). High levels of EPHA2 expression were significantly associated with increased tumor vertical thickness (p = 0.03) and the presence of intrascleral involvement (p = 0.05), whereas high EPHA6 nuclear expression was associated with older age at diagnosis (p = 0.03) and absence of retinal detachment (p = 0.05). In a multivariate survival analysis, increased EPHA4 expression was associated with shortened OS along with the presence of metastasis (p < 0.001) and monosomy 3 (p = 0.02). In a separate model, the concurrent overexpression of at least two of the investigated EPHs (HR = 14.7, p = 0.03) also proved to be an independent poor prognostic factor. In conclusion, our results implicate these specific members of the EPHA group as potential biomarkers for disease prognosis as well as possible targets for the development of novel therapeutic interventions.
Identifiants
pubmed: 35626181
pii: diagnostics12051025
doi: 10.3390/diagnostics12051025
pmc: PMC9139903
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Diagnostics (Basel). 2021 Dec 03;11(12):
pubmed: 34943502
Cancer Metastasis Rev. 2018 Dec;37(4):677-690
pubmed: 30203109
Nat Rev Mol Cell Biol. 2016 Apr;17(4):240-56
pubmed: 26790531
Ophthalmology. 2005 Oct;112(10):1784-9
pubmed: 16154197
Ophthalmology. 2009 Mar;116(3):536-543.e2
pubmed: 19167086
Am J Pathol. 2009 Apr;174(4):1492-503
pubmed: 19264906
Pathol Oncol Res. 2014 Apr;20(2):277-84
pubmed: 24022400
Cells. 2020 Mar 20;9(3):
pubmed: 32244922
J Cell Biol. 2016 Dec 5;215(5):687-703
pubmed: 27903606
Ophthalmology. 1998 Jan;105(1):195-8
pubmed: 9442799
Biomed Res Int. 2018 Feb 28;2018:7390104
pubmed: 29682554
Ophthalmology. 2018 Feb;125(2):203-209
pubmed: 28823399
BMC Clin Pathol. 2013 Jun 05;13(1):19
pubmed: 23738943
Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33
pubmed: 27322403
Arch Ophthalmol. 2005 Dec;123(12):1639-43
pubmed: 16344433
J Cell Biol. 2010 Aug 9;190(3):461-77
pubmed: 20679435
Lancet. 1996 May 4;347(9010):1222-5
pubmed: 8622452
Cell. 1997 Aug 8;90(3):403-4
pubmed: 9267020
Arch Ophthalmol. 2006 Jan;124(1):54-60
pubmed: 16401785
Dig Dis Sci. 2009 Nov;54(11):2410-7
pubmed: 19101799
Cancers (Basel). 2021 Dec 25;14(1):
pubmed: 35008260
Cancer Res. 2016 Nov 15;76(22):6452-6457
pubmed: 27811149
Life (Basel). 2020 Sep 30;10(10):
pubmed: 33007931
Int J Med Sci. 2008 Sep 03;5(5):263-72
pubmed: 18797510
Oncogene. 2011 Dec 15;30(50):4921-9
pubmed: 21666714
BMC Clin Pathol. 2014 Feb 04;14(1):8
pubmed: 24495444
J Cancer. 2017 Apr 9;8(6):1089-1096
pubmed: 28529623
NPJ Precis Oncol. 2021 Sep 30;5(1):89
pubmed: 34593944
Ophthalmology. 2010 Feb;117(2):324-33
pubmed: 19969359
Invest Ophthalmol Vis Sci. 2001 Feb;42(2):313-7
pubmed: 11157859
Cancers (Basel). 2021 Aug 10;13(16):
pubmed: 34439182
Cells. 2021 Jan 31;10(2):
pubmed: 33572586
Oncogene. 2019 Sep;38(39):6567-6584
pubmed: 31406248
Anticancer Res. 2018 Jun;38(6):3273-3282
pubmed: 29848674
Acta Crystallogr D Biol Crystallogr. 2014 Dec 1;70(Pt 12):3135-43
pubmed: 25478832
Cancers (Basel). 2021 Jan 08;13(2):
pubmed: 33430066
Int J Biochem Cell Biol. 2018 Dec;105:123-133
pubmed: 30343150
Int J Mol Sci. 2021 Aug 05;22(16):
pubmed: 34445116
Chin J Cancer Res. 2017 Aug;29(4):303-312
pubmed: 28947862
Oncotarget. 2016 Apr 19;7(16):21362-80
pubmed: 26870995
Oncol Lett. 2019 Nov;18(5):5607-5613
pubmed: 31620202
J Cancer Res Clin Oncol. 2018 Sep;144(9):1649-1663
pubmed: 29948146
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Med Sci Monit. 2011 Sep;17(9):BR257-65
pubmed: 21873938
Oncol Lett. 2018 Apr;15(4):5257-5263
pubmed: 29552165